Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik

Executive Summary

FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.

Advertisement

Related Content

Purdue Highlights Convenience Of New Opioid Induced Constipation Drug Symproic
Valeant's New Strategic Direction: Clean Break Or Simply A Paint Job?
Another Black Cloud Douses Valeant's Sunlight
Keeping Track: Approval Elusive For Biosimilar Neulasta; Valeant Gets A Nod And A No From FDA; Submissions From Amgen, Puma, Bristol
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry
Ackman Warned Valeant 'Rome Was Burning,' Begged 'Tell The Truth'
AZ Alliance Bolsters Daiichi’s US Primary Care Presence
Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest
Relistor Finally Cleared For Bigger Opioid-Induced Constipation Label
AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC096943

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel